Deutscher Krebskongress
10.11.2022
Die GBG ist mit mehreren Postern auf dem 35. Deutschen Krebskongress vom 13. – 16. November 2022 in Berlin vertreten.
GeparPiPPA (GBG105)
GeparPiPPa-A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients with HER2+/HR+, PIK3CA mutant early breast cancer (BC);
Sibylle Loibl; 13. November 2022; 18:00-18:05; Presenter: Sabine Seiler (Abstract-Nr. 1027). Posterdownload
SASCIA (GBG 102)
Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients (pts) with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant chemotherapy (NACT);
Frederick Marmé; 13. November 2022; 18:10-18:15; Presenter: Frederick Marmé. (Abstract-Nr. 504). Posterdownload
BMBC (GBG 79)
Impact of Tucatinib on Progression Free Survival in Patients with HER2 + Metastatic Breast Cancer and Brain Metastases;
Sibylle Loibl; 13. November 2022 18:30-18:35; Presenter: Sibylle Loibl (Abstract-Nr. 309). Posterdownload
News
-
28.09.2023 Translational Work from GeparSepto published
The prognostic and predictive potential of CAV1/2 expression was analysed in the GeparSepto trial (GBG 069).
Mehr ... -
27.09.2023 GBG research at SABCS
GBG will present several posters at the San Antonio Breast Cancer Symposium 2023
Mehr ... -
21.09.2023 New review on Immune Cell Infiltration published
A review from the International Immuno-Oncology Biomarker Working about tumor immunology was published in the journal of pathology.
Mehr ... -
07.09.2023 Save the date! GBG Annual Scientific Meeting 2024
Das 21. Annual Scientific Meeting 2024 wird am 29.2. bis 1.3. in Frankfurt stattfinden.
Mehr ...